Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: Review of current literature

Histopathology

Volumn 47, Issue 1, 2005, Pages 1-16

  Varma, M ^a   Jasani, B ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

AMACR; High molecular weight cytokeratin; Immunohistochemistry; p63; Prostate

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 1; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; PROTEIN P63; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; UROPLAKIN;

ACINAR CELL CARCINOMA; BLADDER CARCINOMA; BREAST ADENOCARCINOMA; CARCINOID; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYSTITIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEEDLE BIOPSY; PANCREAS ISLET CELL TUMOR; PERIANAL GLAND; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUALITY CONTROL; REVIEW; SALIVARY GLAND TUMOR; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 22144496489     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02188.x     Document Type: Review

References (110)

1. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod. Pathol. 2004; 17; 328-348.
2. Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PG et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch. Pathol. Lab. Med. 2002; 126; 554-561.
3. Totten RS, Heinemann MW, Hudson PB, Sproul EE, Stout AP. Microscopic differential diagnosis of latent carcinoma of prostate. AMA Arch. Pathol. 1953; 55; 131-141.
4. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am. J. Surg. Pathol. 1995; 19; 251-260.
5. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI. Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology 1995; 45; 981-986.
6. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am. J. Surg. Pathol. 2002; 26; 1161-1168.
7. Berney DM, Varma M, Jasani B, Rhodes A. Which basal cell marker? A survey of prostatic basal cell markers used in the UK. J. Pathol. 2005; 205(suppl.); 14A (Abstract).
8. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology 2002; 41; 35-41.
9. Freeman A, Treurnicht K, Munson P, Miller K, Parkinson MC. A comparison of basal cell markers used in the prostate. Histopathology 2002; 40; 492-494.
10. Shah IA, Schlageter MO, Stinnett P, Lechago J. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod. Pathol 1991; 4; 220-224.
11. Varma M, Linden MD, Amin MB. Effect of formalin fixation and epitope retrieval techniques on antibody 34betaE12 immunostaining of prostatic tissues. Mod. Pathol. 1999; 12; 472-478.
12. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am. J. Surg. Pathol. 1999; 23; 147-152.
13. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am. J. Surg. Pathol. 2002; 26; 1151-1160.
14. Goldstein NS, Underbill J, Roszka J, Neill JS. Cytokeratin 34 beta E-12 immunoreactivity in benign prostatic acini. Quantitation, pattern assessment, and electron microscopic study. Am. J. Clin. Pathol. 1999; 112; 69-74.
15. Amin MB, Tamboli P, Varma M, Srigley JR. Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am. J. Surg. Pathol. 1999; 23; 925-931.
16. Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am. J. Surg. Pathol. 1995; 19; 737-747.
17. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59; 788-794.
18. Levi AW, Epstein JI. Pseudohyperplastic prostatic adenocarcinoma on needle biopsy and simple prostatectomy. Am. J. Surg. Pathol. 2000; 24; 1039-1046.
19. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am. J. Surg. Pathol. 1996; 20; 419-426.
20. Cina SJ, Epstein JI. Adenocarcinoma of the prostate with atrophic features. Am. J. Surg. Pathol. 1997; 21; 289-295.
21. Brawer MK, Nagle RB, Pitts W, Freiha F, Gamble SL. Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer 1989; 63; 454-460.
22. Signoretti S, Waltregny D, Dilks J et al. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000; 157; 1769-1775.
23. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001; 58; 619-624.
24. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 2002; 15; 1302-1308.
25. Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000; 60; 1677-1682.
26. Jiang Z, Woda BA, Rock KL et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 2001; 25; 1397-1404.
27. Evans AJ. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J. Clin. Pathol. 2003; 56; 892-897.
28. Zhou M, Aydin H, Kanane H, Epstein JI. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am. J. Surg. Pathol. 2004; 28; 239-243.
29. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am. J. Clin. Pathol. 2004; 122; 275-289.
30. Luo J, Zha S, Gage WR, Dunn TA et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002; 62; 2220-2226.
31. Rubin MA, Zhou M, Dhanasekaran SM et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287; 1662-1670.
32. Jiang Z, Wu CL, Woda BA et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am. J. Surg. Pathol. 2002; 26; 1169-1174.
33. Beach R., Gown AM, De Peralta-Venturina MN et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am. J. Surg. Pathol. 2002; 26; 1588-1596.
34. Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am. J. Clin. Pathol. 2003; 120; 737-745.
35. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am. J. Surg. Pathol. 2003; 27; 1128-1133.
36. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am. J. Surg. Pathol. 2003; 27; 772-778.
37. Jiang Z, Wu CL, Woda BA et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 2004; 45; 218-225.
38. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum. Pathol. 2004; 35; 1272-1278.
39. Kunju LP, Rubin MA, Shen R., Ingold C, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha-methylacyl-CoA- racemase in benign, atypical and malignant prostate tissues. Mod. Pathol. 2003; 16; 158A (Abstract).
40. Wu CL, Yang XJ, Tretiakova M et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum. Pathol. 2004; 35; 1008-1013.
41. Postma R, Roobol M, Schroder FH, van der Kwast TH. Lesions predictive for prostate cancer in a screened population: first and second screening round findings. Prostate 2004; 61; 260-266.
42. Naya Y, Ayala AG, Tamboli P, Babaian RJ. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urology 2004; 63; 503-508.
43. Yang XJ, Wu CL, Woda BA et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am. J. Surg. Pathol 2002; 26; 921-925.
44. Gupta N, de Peralta-Venturina M, Gown AM et al. P504S antibody expression in putative precursor lesions of prostate carcinoma-high grade intraepithelial neoplasia and atypical adenomatous hyperplasia. Mod. Pathol. 2003; 16; 152A (Abstract).
45. Epstein JI, Yang XJ. Prostate biopsy interpretation, 3rd edn. Philadelphia: Lippincott Williams & Wilkins 2002.
46. Gupta A, Wang HL, Policarpio-Nicolas ML et al. Expression of alpha-methylacyl-coenzyme a racemase in nephrogenic adenoma. Am. J. Surg. Pathol. 2004; 28; 1224-1229.
47. Skinnider BF, Oliva E, Young RH, Amin MB. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am. J. Surg. Pathol. 2004; 28; 701-705.
48. Davis CJ, Furusato B, Sesterhenn IA. Alpha-methylacyl-COA-racemase: expression levels of this novel cancer biomarker in nephrogenic adenoma. Mod. Pathol. 2004; 17; 147A (Abstract).
49. Allan CH, Epstein JI. Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. Am. J. Surg. Pathol. 2001; 25; 802-808.
50. Gilcrease MZ, Delgado R, Vuitch F, Albores-Saavedra J. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum. Pathol. 1998; 29; 1451-1456.
51. Molinie V, Fromont G, Sibony M et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod. Pathol. 2004; 17; 1180-1190.
52. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of 'suspicious' foci in prostatic needle biopsy specimens. Am. J. Clin. Pathol. 2004; 121; 99-107.
53. Zhou M, Shah R., Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am. J. Surg. Pathol. 2003; 27; 365-371.
54. Jiang Z, Woda BA, Dresser K, Li C. An immunohistochemical study with triple antibodies and two color reactions on a single slide for the detection of small focal prostate carcinoma on needle biopsies. Mod. Pathol. 2004; 17; 160A (Abstract).
55. Hameed O, Sublett J, Humphrey PA. A comparison of p63, AMACR, and a cocktail comprising of both, in the diagnosis of prostatic carcinoma. Mod. Pathol. 2004; 17; 156A (Abstract).
56. Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J. Clin. Pathol. 2004; 57; 687-690.
57. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA. Implications for diagnostic prostatic pathology. Am. J. Clin. Pathol. 2002; 118; 202-207.
58. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol. 2002; 117; 471-477.
59. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum. Pathol. 2002; 33; 1136-1140.
60. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 1991; 145; 907-923.
61. Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol. Clin. North Am. 1993; 20; 757-770.
62. Zaviacic M, Sidlo J, Borovsky M. Prostate specific antigen and prostate specific acid phosphatase in adenocarcinoma of Skene's paraurethral glands and ducts. Virchows Arch. A Pathol. Anat. Histopathol. 1993; 423; 503-505.
63. Nowels K, Kent E, Rinsho K, Oyasu R. Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis. Arch. Pathol. Lab. Med. 1988; 112; 734-737.
64. Kamoshida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum. Pathol. 1990; 21; 1108-1111.
65. Frazier HA, Humphrey PA, Burchette JL, Paulson DF. Immunoreactive prostatic specific antigen in male periurethral glands. J. Urol 1992; 147; 246-248.
66. Golz R, Schubert GE. Prostatic specific antigen: immunoreactivity in urachal remnants. J. Urol. 1989; 141; 1480-1482.
67. Cina SJ, Silberman MA, Kahane H, Epstein JI. Diagnosis of Cowper's glands on prostate needle biopsy. Am. J. Surg. Pathol. 1997; 21; 550-555.
68. Varma M, Morgan M, O'Rourke D, Jasani B. Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) immunoreactivity in benign seminal vesicle/ejaculatory duct epithelium: a potential pitfall in the diagnosis of prostate cancer in needle biopsy specimens. Histopathology 2004; 44; 405-406.
69. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells. Anticancer Res. 1997; 17; 2577-2581.
70. Alanen KA, Kuopio T, Collan YU, Kronqvist P, Juntti L, Nevalainen TJ. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. Breast Cancer Res. Treat. 1999; 56; 169-176.
71. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are coexpressed in androgen receptor-positive breast tumours. Br. J. Cancer 1998; 78; 360-365.
72. Howarth DJ, Aronson IB, Diamandis EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br. J. Cancer 1997; 75; 1646-1651.
73. Tazawa K, Kurihara Y, Kamoshida S, Tsukada K, Tsutsumi Y. Localization of prostate-specific antigen-like immunoreactivity in human salivary gland and salivary gland tumors. Pathol. Int. 1999; 49; 500-505.
74. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am. J. Surg. Pathol. 2000; 24; 579-586.
75. Holmes GF, Eisele DW, Rosenthal D, Westra WH. PSA immunoreactivity in a parotid oncocytoma: a diagnostic pitfall in discriminating primary parotid neoplasms from metastatic prostate cancer. Diagn. Cytopathol. 1998; 19; 221-225.
76. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991; 67; 2165-2172.
77. Wilbur DC, Krenzer K, Bonfiglio TA. Prostate specific antigen (PSA) staining in carcinomas of non-prostatic origin. Am. J. Clin. Pathol. 1987; 88; 530 (Abstract).
78. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas. Anticancer Res. 1997; 17; 2343-2346.
79. Kuopio T, Ekfors TO, Nikkanen V, Nevalainen TJ. Acinar cell carcinoma of the pancreas. Report of three cases. APMIS 1995; 103; 69-78.
80. Yam LT, Janckila AJ, Lam WK, Li CY. Immunohistochemistry of prostatic acid phosphatase. Prostate 1981; 2; 97-107.
81. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J. Urol. 1996; 156; 464-468.
82. Van Krieken JHJM. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am. J. Surg. Pathol. 1993; 17; 410-414.
83. James GK, Pudek M, Berean KW, Diamandis EP, Archibald BL. Salivary duct carcinoma secreting prostate-specific antigen. Am. J. Clin. Pathol. 1996; 106; 242-247.
84. Epstein JI, Kuhajda FP, Lieberman PH. Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum. Pathol. 1986; 17; 939-942.
85. Choe BK, Pontes EJ, Rose NR, Henderson MD. Expression of human prostatic acid phosphatase in a pancreatic islet cell carcinoma. Invest. Urol. 1978; 15; 312-318.
86. Kimura N, Sasano N. Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch. A Pathol. Anat. Histopathol. 1986; 410; 247-251.
87. Azumi N, Traweek ST, Battifora H. Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. Am. J. Surg. Pathol. 1991; 15; 785-790.
88. Sobin LH, Hjermstad BM, Sesterhenn IA, Helwig EB. Prostatic acid phosphatase activity in carcinoid tumors. Cancer 1986; 58; 136-138.
89. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am. J. Surg. Pathol. 2002; 26; 926-931.
90. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod. Pathol. 2000; 13; 1186-1191.
91. Varma M, Morgan M, Amin MB, Wozniak S, Jasani B. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology 2003; 42; 167-172.
92. Lindeman N, Weidner N. Immunohistochemical profile of prostatic and urothelial carcinoma: impact of heat-induced epitope retrieval and presentation of tumors with intermediate features. Appl. Immunohistochem. 1996; 4; 264-275.
93. Torenbeek R, Lagendijk JH, Van Diest PJ, Bril H, van de Molengraft FJ, Meijer CJ. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998; 32; 20-27.
94. Ordonez NG. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology 2000; 36; 433-438.
95. Cheville JC. Urothelial carcinoma of the prostate. An immunohistochemical comparison with high grade prostatic adenocarcinoma and review of the literature. J. Urol. Pathol. 1998; 9; 141-154.
96. Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl. Immunohistochem. 1995; 3; 99-107.
97. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial and merkel cell carcinomas. Mod. Pathol. 1995; 8; 384-388.
98. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 2000; 13; 962-972.
99. Parker DC, Folpe AL, Bell J et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am. J. Surg. Pathol. 2003; 27; 1-10.
100. Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am. J. Clin. Pathol. 2000; 113; 383-388.
101. Yaziji H, Davie PL, Gown AM. On the use of cytokeratins 7 and 20 in the differentiation between transitional cell carcinoma and prostate adenocarcinoma. Am. J. Clin. Pathol. 2001; 115; 159-160.
102. Appleton MA, Attanoos RL, Jasani B. Thrombomodulin as a marker of vascular and lymphatic tumours. Histopathology 1996; 29; 153-157.
103. Ordonez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology 1997; 31; 25-30.
104. Ascoli V, Scalzo C, Taccogna S, Nardi F. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch. Pathol. Lab. Med. 1995; 1995; 1136-1140.
105. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am. J. Clin. Pathol. 1998; 110; 385-390.
106. Moll R, Laufer J, Wu XR, Sun TT. [Uroplakin III, a specific membrane protein of urothelial umbrella cells, as a histological markers for metastatic transitional cell carcinomas]. Verh. Dtsch. Ges. Pathol. 1993; 77; 260-265.
107. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am. J. Clin. Pathol. 2000; 113; 683-687.
108. Oliai BR, Kahane H, Epstein JI. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. Am. J. Surg. Pathol. 2001; 25; 794-801.
109. Varma M, Morgan M, Amin MB, Wozniak S, Jasani B. High-molecular-weight cytokeratin antibody (clone 34betaE12) as a urothelial marker: a note of caution. Histopathology 2004; 44; 189-190.
110. Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am. J. Surg. Pathol. 2004; 28; 651-657.